Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2015

View Archived Issues

Bayer Schering Pharma discloses CCR2 antagonists

Vectus Biosystems patents novel compounds for hypertension and fibrosis

BIIB-037 shows promising results as a disease-modifying treatment in AD patients

4E-T identified as potential prognostic marker in breast carcinoma

JCR Pharma prepares for clinical development of sustained growth hormone formulation

PI3Kbeta inhibitors show promise for the treatment of PTEN-mutated tumors

Pharmacyclics patents BTK inhibitors

Daiichi Sankyo reports development of novel Nrf2 activators by biotransformation

Recro Pharma acquires injectable meloxicam for pain

Cipher Pharmaceuticals acquires dermatology company INNOCUTIS

Merck & Co. discloses novel HCV NS5A inhibitor

DiscoveryBioMed developing dual-action small-molecule monotherapy for cystic fibrosis

SBIR grant supports Xeris' development of stable non-aqueous glucagon for congenital hyperinsulinism

Lummy HK licenses Chinese rights to AGS-003 and Argos' Arcelis technology

Menarini licenses resminostat for development and marketing in Asia-Pacific excluding Japan

Astellas to collaborate with Ventana Medical Systems on companion diagnostic tests

Esperas Pharma launched to develop anticancer compound discovered at Lilly

Roche introduces mGlu4 receptor PAMs

Sunshine Lake Pharma patent describes SGLT2 inhibitors

Bayer Schering Pharma presents FXIa inhibitors

Columbia Laboratories changes name to Juniper Pharmaceuticals

Soligenix and FDA agree on protocol for phase III trial of SGX-203 for pediatric Crohn's disease

EMA approves compassionate use of OMS-721 in patients with aHUS

FDA grants orphan drug status to tremelimumab for malignant mesothelioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...